Back to Newsroom

Preclinical Data Support Endocyte’s Folate Receptor-Targeted Small Molecule Drug Conjugates for Treatment of Triple Negative Breast Cancer

WEST LAFAYETTE, Ind., Dec. 16, 2013 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced preclinical data suggesting the company’s folate receptor-targeted SMDCs may provide a possible new treatment alternative for folate receptor expressing triple negative breast cancer (TNBC) patients. The preclinical data were presented on Dec. 12 at the 2013 Cancer Therapy & Research Center — American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium in San Antonio, Texas.